The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1547
ISSUE1547
May 21, 2018
Trelegy Ellipta - A Three-Drug Inhaler for COPD
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Trelegy Ellipta - A Three-Drug Inhaler for COPD
May 21, 2018 (Issue: 1547)
The FDA has approved Trelegy Ellipta (GSK), a fixed-dose
combination of the inhaled corticosteroid (ICS)
fluticasone furoate, the long-acting antimuscarinic
agent (LAMA) umeclidinium, and the long-acting
beta2-agonist (LABA) vilanterol. It is...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.